Markets
Trump Tariffs
(Chip Somodevilla/Getty Images)

Trump was right, at least about this

Japanese carmakers are eating the bulk of the 25% tariffs the administration slapped on its exports to the US, in a remarkably Trumpian violation of the laws of economics.

7/17/25 12:27PM

Sometimes it seems like there’s no law — economic, political, constitutional, societal, you name it — that can withstand President Donald Trump’s reality distortion field.

For instance, economists and journalists steeped in the economic theory that dominated pre-Trump American policymaking almost universally dismissed his assertions that foreigners would pay for the massive on-again, off-again tariffs that whipsawed the markets and consumer sentiment recently.

The president’s stance, they said, betrayed his basic ignorance about how tariffs work, which is that the tariffs are paid by US importers when they take possession of the foreign goods they’ve ordered at US ports. The importers then pass those costs along to US consumers in the form of higher prices.

As a technical matter, all true. But it was too simple of a story, implying a near automatic pass-through of tariffs to higher consumer prices and ultimately inflation.

That story ignored another potential. It’s quite possible that some part of the tariffs would, indeed, be more or less paid by foreign producers who are worried that high tariffs would make their goods too expensive for Americans, costing them market share in the US.

One solution: they could cut their prices, essentially paying for some of the tariffs by reducing their profit margins.

And that seems to be what some of the world’s most sophisticated exporters, Japanese automakers, are doing. Goldman Sachs analysts following the Japanese economy recently spotlighted this chart showing the plunge in the price of Japanese passenger car exports to North America compared to prices in the rest of the world.

The export price index for vehicles exported to North America plunged nearly 20% in June, the largest drop on records going back to 2016, according to The Japan Times.

Goldman analysts remarked that the price cut “suggests that, at least for now, Japanese automakers have chosen to absorb the majority of the +25 percentage point additional tariff themselves, thereby mitigating a rise in US selling prices.”

This sort of decision is “inconsistent with the view in recent years that US consumers and businesses ultimately bear the full burden of US tariffs via higher US domestic prices.”

So, what gives? Well, Goldman analysts poked through broader data on Japanese exports and found that few other Japanese exporters cut prices like this in response to the tariffs.

Perhaps, they wrote, the decline in car export prices reflects the retail nature of the car market, where shoppers experience price hikes personally. Or maybe it has to do with the fact that price adjustments are typically done during model year changeovers. Or it could be that “Japanese automakers may be adopting a wait-and-see approach, avoiding price revisions in the US until diplomatic negotiations between Japan and the US are concluded.”

At any rate, there are likely to be limits to how long it can last before profitability plunges, forcing a shift in management strategy.

But investors — and economists — might want to reflect on what all this means.

If Japanese companies are willing to eat some of Trump’s tariffs, it seems likely some US companies, which have seemingly bowed to the government on any number of fronts since Trump took office, would also sacrifice some profits rather than risk attracting the president’s ire. Trump has already personally demanded automakers and Walmart refrain from raising prices. If they comply, it would mean bad things for Corporate America’s bottom line.

And for those economists out there, it would obviously have implications for whether the widespread tariff-driven inflation that everyone was predicting a couple months ago ever actually materializes. (So far, it hasn’t.)

At any rate, it’s all worth keeping an eye on as we go through earnings season.

More Markets

See all Markets
markets

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.